ABCL Stock Recent News

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Present at the Goldman Sachs 44th Annual Global Healthcare Conference on June 13, 2023.

While the recent slow activity in the major indices clouds the narrative, you can still enjoy opportunities for growth stocks that could double your money. To be sure, you must be willing to accept some risks.

AbCellera reported results from the first quarter on May 4th. To put it bluntly, the actual earnings print means next to nothing in this name at this stage. The company had a very busy and productive quarter under the surface, reporting progress on multiple fronts, specifically the TCE program (T-cell engager).

AbCellera Biologics Inc. (NASDAQ:ABCL ) Q1 2023 Results Conference Call May 4, 2023 5:00 PM ET Company Participants Tryn Stimart - Chief Legal and Compliance Officer Dr. Carl Hansen - Chairman, Chief Executive Officer, and President Andrew Booth - Chief Financial Officer Conference Call Participants Andrea Tan - Goldman Sachs Antonia Borovina - Bloom Burton Stephen Willey - Stifel Nishant Gandhi - Truist Gaurav Goparaju - Berenberg Puneet Souda - SVB Securities Malcolm Hoffman - BMO Steven Mah - Cowen Operator Good afternoon. And welcome to AbCellera's First Quarter 2023 Business Update Conference Call.

AbCellera Biologics Inc. (ABCL) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to earnings of $0.54 per share a year ago.

Generally speaking, you get what you pay for, which on paper doesn't bode well for these bargain stocks under $10. Nevertheless, with thousands upon thousands of tradable securities available to public investors, at least a few will go unnoticed.

Although financial advisors often direct you to established, reliable enterprises, in some cases, you can find compelling ideas among the best stocks under $10. To be fair, such companies tend to be more volatile than your standard blue-chip fare.

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Present at the 2023 Bloom Burton & Co.

While it might be difficult to navigate the equities sector now amid various headwinds, biotech stocks to buy may offer a surprising respite. True, the market presence of the surprise production cuts by the Organization of the Petroleum Exporting Countries (OPEC) and non-member oil-producing nations — known as OPEC+ — along with the Federal Reserve's possible response.

Most readers follow my work for the extensive writing I have done referencing my aggressive growth portfolio. However, the vast majority of my net worth is held in my all-weather portfolio. In this article, I would like to draw back the curtain on my main, all-weather portfolio, where roughly 80% of my assets reside.